In 2020, the US government launched a number of drug importation-focused initiatives aimed at addressing high drug costs in the US. In September, as part of its Safe Importation Action Plan, FDA issued a final rule allowing importation of certain prescription drugs from Canada, along with a final guidance for importing prescription drugs originally intended for foreign markets. The Most Favored Nation executive order, released in November, limits the reimbursement rates for CMS to rates paid by other countries. In this webinar, panelists will take stock of the new state of drug importation, especially in light of COVID-19, and its potential impact to the US drug market. The discussion will include an in-depth review of both actions, focusing on the Safe Importation Action Plan and how Canadian regulators and manufacturers have responded, the risks of foreign unapproved drugs, and the potential impact to US pricing, approvals, and innovation.